Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Breast Neoplasms × elacestrant × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Trastuzumab 6 Fulvestrant 6 Capecitabine 6 abemaciclib 5 trastuzumab deruxtecan 4 eribulin 4 Paclitaxel 4 Gemcitabine 4 sacituzumab govitecan 3 Vinorelbine 3 Docetaxel 3 Cyclophosphamide 3 selpercatinib 2 ribociclib 2 pertuzumab 2 olaparib 2 exemestane 2 Letrozole 2 Fluorouracil 2 Epirubicin 2 Doxorubicin 2 Anastrozole 2 Ado-Trastuzumab Emtansine 2 130-nm albumin-bound paclitaxel 2 tucatinib 1 talazoparib 1 palbociclib 1 neratinib 1 larotrectinib 1 inavolisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03778931 2025-09-15

EMERALD

Stemline Therapeutics, Inc.

Phase 3 Completed

478 enrolled 16 charts 1 FDA

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡